Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7331382 | 1.00 | CES2 (0.44) | CES2CES1HSD11B1NAAAHDAC8 | |
| SCHEMBL7339919 | 0.98 | CES2 (0.40) | CES2CES1HSD11B1NAAAHDAC8 | |
| SCHEMBL8385049 | 0.93 | — | — | |
| SCHEMBL1678457 | 0.88 | — | — | |
| SCHEMBL7303987 | 0.83 | CES2 (0.41) | CES2CES1HSD11B1NAAAHDAC8 | |
| SCHEMBL8386944 | 0.80 | NAAA (0.38) | CES2CES1HSD11B1NAAAHDAC8 | |
| SCHEMBL7299667 | 0.79 | NAAA (0.46) | CES2CES1NAAAEPHX1 | |
| SCHEMBL3927737 | 0.78 | TSHR (0.46) | ALDH1A1TSHREPHX1SMN1; SMN2MEN1 | |
| SCHEMBL7312858 | 0.78 | NAAA (0.49) | CES2CES1NAAAEPHX1 | |
| SCHEMBL9238982 | 0.77 | CES2 (0.44) | CES2CES1HSD11B1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417787-B | Extractant for rapidly and efficiently separating and extracting strontium and preparation method thereof | 四川大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-115417787-A | Extractant for rapidly and efficiently separating and extracting strontium and preparation method thereof | 四川大学 | 2022-12-02 | — | — | CN | disclosed |
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | EMORY UNIVERSITY | 2002-09-12 | — | — | US | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| US-4756741-A | Azolyloxy-carboxylic acid amide compounds and herbicidal compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1988-07-12 | — | — | US | disclosed |
| US-4218378-A | 11a-Methano-TXA compounds | THE UPJOHN COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
| US-4140863-A | 9,11-Dihalo-PG2 compounds | THE UPJOHN COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4118584-A | 9-Deoxy-9-methylene-16-phenyl-PGF compounds | THE UPJOHN COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4110532-A | PROSTAGLANDINS, SMOOTH MUSCLE STIMULANTS | THE UPJOHN COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4098805-A | 9-DEOXY-9-METHYLENE-PGF-TYPE AMIDES | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128208-A1 | Nonpeptide agonists and antagonists of vasopressin receptors | AVPR1A, AVPR2, AVPR1B | CES2 3090/4885CES1 2288/4885HSD11B1 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.